GO:0001519 peptide amidation: Peptide Hormone Maturation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001519 peptide amidation is the posttranslational conversion of C-terminal glycine-extended peptides into C-terminal alpha-amidated peptides, a modification required for the bioactivity of over half of all peptide hormones.
• The reaction proceeds in two steps: peptidyl-glycine alpha-hydroxylating monooxygenase (PHM) hydroxylates the C-terminal glycine, then peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL) cleaves the intermediate to release the amidated peptide.
• In higher organisms, both enzymatic activities reside on a single bifunctional polypeptide, peptidylglycine alpha-amidating monooxygenase (PAM), whereas in some organisms the steps are catalyzed by separate enzymes.
• Amidation is critical for peptide hormone signaling and has been documented in pro-ACTH/endorphin-derived peptides such as joining peptide and in peptide hormones produced by lung cancer cells.
• Dysregulated peptide amidation contributes to cancer biology, as alpha-amidation of peptide hormones has been observed in lung cancer, and amidation can modulate amyloid-beta aggregation relevant to neurodegeneration.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of peptide amidation genes and their roles in disease [2,3].
Description
Peptide amidation (GO:0001519) is a posttranslational modification that converts C-terminal glycine-extended peptides into C-terminal alpha-amidated peptides, a change that is essential for the biological activity of more than half of all peptide hormones. This process is catalyzed by a two-step enzymatic mechanism involving a peptidyl-glycine alpha-hydroxylating monooxygenase and a peptidyl-alpha-hydroxyglycine alpha-amidating lyase; in higher organisms, a single bifunctional polypeptide, peptidylglycine alpha-amidating monooxygenase (PAM), carries out both reactions. The importance of this modification is underscored by its occurrence on pro-ACTH/endorphin-derived peptides such as joining peptide and by its detection in peptide hormones secreted by lung cancer cells. Researchers study peptide amidation to understand how neuroendocrine and endocrine signaling peptides acquire their mature, bioactive forms and how disruption of this process contributes to disease. Because amidation is often required for receptor binding and stability, it represents a critical node in peptide hormone biology and a potential target for therapeutic intervention [2,3]. The availability of CRISPR-based genome editing tools now allows precise interrogation of the genes and enzymes that govern this pathway, linking molecular mechanisms to physiological and pathological outcomes [2,3].
peptide amidation At A Glance
| GO ID | GO:0001519 |
|---|---|
| GO term | peptide amidation |
| Ontology | biological_process |
| Synonym | None |
| Major function | Posttranslational conversion of C-terminal glycine-extended peptides to C-terminal alpha-amidated peptides, essential for bioactivity of over half of all peptide hormones |
| Enzymatic steps | Two-step process catalyzed by peptidyl-glycine alpha-hydroxylating monooxygenase and peptidyl-alpha-hydroxyglycine alpha-amidating lyase |
| Enzyme architecture | In higher organisms, one bifunctional polypeptide (PAM) catalyzes both reactions; in some organisms, two separate enzymes are used |
| Representative substrate | Joining peptide, a major pro-ACTH/endorphin-derived product peptide |
| Disease relevance | Alpha-amidation of peptide hormones in lung cancer; amidation effects on amyloid-beta aggregation |
What Is GO:0001519?
According to the Gene Ontology, peptide amidation (GO:0001519) is defined as the posttranslational conversion of C-terminal glycine-extended peptides to C-terminal alpha-amidated peptides. This modification occurs on over half of all peptide hormones to yield bioactive peptides. The process is a two-step reaction: first, a peptidyl-glycine alpha-hydroxylating monooxygenase hydroxylates the C-terminal glycine; second, a peptidyl-alpha-hydroxyglycine alpha-amidating lyase cleaves the hydroxylated intermediate to produce the alpha-amidated peptide. In some organisms, these two steps are catalyzed by separate enzymes, whereas in higher organisms a single polypeptide catalyzes both reactions.
Why Is peptide amidation Important in Cell Biology?
Peptide amidation is a decisive step in the maturation of many signaling peptides, and without it, numerous hormones and neuropeptides remain inactive or unstable. The modification is required for over half of all peptide hormones to achieve bioactivity, making it a central node in endocrine and neuroendocrine physiology. Its occurrence on pro-ACTH/endorphin-derived joining peptide illustrates its role in the processing of large precursor proteins into functional products. In cancer, alpha-amidation of peptide hormones has been detected in lung cancer, suggesting that tumor cells can exploit this pathway for autocrine or paracrine signaling. Furthermore, amidation can influence the aggregation of amyloid-beta peptides, linking this modification to neurodegenerative processes. Consequently, understanding peptide amidation provides mechanistic insight into hormone action, cancer biology, and neurodegeneration, and it offers a target for therapeutic modulation [2,3,7].
• Required for the bioactivity of over half of all peptide hormones.
• Converts inactive glycine-extended precursors into active alpha-amidated peptides.
• Plays a role in processing pro-ACTH/endorphin-derived peptides such as joining peptide.
• Detected in peptide hormones produced by lung cancer cells, implicating it in tumor biology.
• Modulates amyloid-beta aggregation, relevant to Alzheimer's disease and neurodegeneration.
• Represents a potential target for modulating hormone signaling in endocrine disorders.
• Can be studied using enzymatic transacylation and photolysis approaches for synthetic or analytical purposes.
• Amidation chemistry is exploited in peptide and dendrimer design, with broader biotechnological applications.
• Twisted amide-mediated peptide synthesis provides chemical insights into amide bond formation relevant to amidation.
• Peptide-directed solid-phase reductive amination offers tools for site-specific modification.
What Happens During peptide amidation?
Step 1: Hydroxylation of the C-terminal glycine
In simple terms: First, an enzyme adds an oxygen atom to the terminal glycine of the peptide.
The first step of peptide amidation is catalyzed by peptidyl-glycine alpha-hydroxylating monooxygenase (PHM), which hydroxylates the alpha-carbon of the C-terminal glycine residue, converting it to a peptidyl-alpha-hydroxyglycine intermediate. This reaction requires molecular oxygen and ascorbate as cofactors and occurs in the secretory pathway. In higher organisms, PHM activity is part of the bifunctional PAM enzyme.
Step 2: Cleavage to release the alpha-amidated peptide
In simple terms: Second, another enzyme cuts the modified intermediate to leave an amide group at the peptide's end.
The second step is catalyzed by peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL), which cleaves the peptidyl-alpha-hydroxyglycine intermediate, releasing the C-terminal alpha-amidated peptide and glyoxylate. This step completes the conversion of the glycine-extended precursor to the bioactive amidated product. In higher organisms, PAL activity resides on the same polypeptide as PHM.
Enzyme architecture: bifunctional versus separate enzymes
In simple terms: In humans and many higher organisms, one protein does both steps; in some other organisms, two separate proteins are needed.
In higher organisms, a single bifunctional polypeptide, peptidylglycine alpha-amidating monooxygenase (PAM), catalyzes both the hydroxylation and the lyase reactions. In some organisms, these two activities are carried by separate enzymes. This architectural difference reflects evolutionary adaptation and influences how the pathway is regulated and studied across species.
Substrate specificity and precursor processing
In simple terms: The process acts on many different peptide precursors, including those that give rise to hormones like ACTH and endorphins.
Peptide amidation occurs on a wide range of peptide precursors that have a C-terminal glycine extension. A well-characterized example is joining peptide, a major pro-ACTH/endorphin-derived product peptide that undergoes amidation. The presence of a C-terminal glycine is a key recognition determinant for the amidation machinery, and the reaction is essential for generating mature bioactive peptides from larger precursors.
Occurrence in cancer and disease contexts
In simple terms: Tumors can also use this process to produce active hormones, which may affect cancer growth.
Alpha-amidation of peptide hormones has been observed in lung cancer, indicating that tumor cells can process peptide precursors to bioactive amidated forms. This suggests that peptide amidation may contribute to autocrine or paracrine signaling in cancer. Additionally, amidation can influence the aggregation of amyloid-beta peptides, linking this modification to neurodegenerative disease mechanisms.
Key Genes Involved in GO:0001519 peptide amidation
The following genes and proteins are central to peptide amidation (GO:0001519) or serve as key substrates and research models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PAM | Bifunctional enzyme with PHM and PAL activities that catalyzes both steps of peptide amidation | Primary target for knockout, knock-in, and point-mutation studies to dissect amidation in hormone processing |
| POMC | Precursor protein that gives rise to pro-ACTH/endorphin-derived peptides including joining peptide, a substrate for amidation | Model substrate for studying amidation of endogenous prohormones |
| PCSK1 | Prohormone convertase involved in precursor cleavage prior to amidation | Used in co-expression studies to reconstitute peptide maturation pathways |
| PCSK2 | Prohormone convertase that processes pro-ACTH/endorphin precursors | Relevant for understanding sequential processing steps before amidation |
| Cpe | Carboxypeptidase E removes basic residues to expose C-terminal glycine for amidation | Knockout models help define the requirement for glycine extension in amidation |
| PAM (PHM domain) | Peptidyl-glycine alpha-hydroxylating monooxygenase activity | Domain-specific mutations can separate hydroxylation from lyase function |
| PAM (PAL domain) | Peptidyl-alpha-hydroxyglycine alpha-amidating lyase activity | Target for point mutations that block the second step of amidation |
| AMID | Putative amidase domain-containing protein with possible roles in amidation-related pathways | Explored in cancer contexts where peptide amidation is dysregulated |
| APP | Amyloid precursor protein; its derived amyloid-beta peptides can be amidated, affecting aggregation | Used to study amidation effects on neurodegeneration |
| Aβ(25-35) | Amidated fragment of amyloid-beta that shows altered aggregation properties | Model peptide for biophysical studies of amidation in neurodegeneration |
| PAM-1 | Splice variant of PAM with distinct trafficking and activity | Isoform-specific knockout or knock-in models |
| PAM-2 | Splice variant of PAM with distinct tissue distribution | Used to study isoform-specific functions in vivo |
| PAM-3 | Splice variant of PAM with alternative domain composition | Relevant for understanding differential substrate handling |
| PAM-4 | Splice variant of PAM with unique C-terminal sequences | Target for isoform-specific CRISPR editing |
| PAM-5 | Splice variant of PAM with distinct regulatory properties | Used in overexpression and rescue experiments |
| PAM-6 | Splice variant of PAM with tissue-specific expression | Model for studying context-dependent amidation |
| PAM-7 | Splice variant of PAM with alternative exon usage | Relevant for precise knock-in of tagged isoforms |
| PAM-8 | Splice variant of PAM with distinct enzymatic efficiency | Used to dissect structure-function relationships |
How Is peptide amidation Regulated?
Peptide amidation is regulated at multiple levels, including enzyme expression, substrate availability, and cofactor supply. The bifunctional PAM enzyme requires molecular oxygen, ascorbate, and copper for optimal activity, and its expression is tissue-specific and often coordinated with prohormone convertases that generate glycine-extended substrates. In cancer, amidation of peptide hormones can be upregulated, as seen in lung cancer, suggesting that tumor microenvironment or oncogenic signaling may influence pathway activity. Additionally, the presence of amidation in amyloid-beta peptides indicates that pathological conditions can alter the amidation state of specific substrates. However, specific transcriptional or signaling regulators (e.g., mTOR, ISR) of peptide amidation are not well-defined in the provided literature, and further research is needed to establish direct regulatory mechanisms [2,3,7].
peptide amidation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PAM | Peptide hormone bioactivity and endocrine disorders | Knockout and knock-in models to assess hormone processing |
| POMC | Pro-ACTH/endorphin processing and joining peptide amidation | Point mutations at the C-terminal glycine to block amidation |
| AMID | Lung cancer and peptide hormone amidation | Overexpression and knockout in lung cancer cell lines |
| APP | Amyloid-beta aggregation in neurodegeneration | Amidated Aβ(25-35) peptide treatment in neuronal cultures |
| PCSK1 | Prohormone processing disorders | CRISPR knockout to study precursor cleavage prior to amidation |
Peptide amidation in cancer
Alpha-amidation of peptide hormones has been detected in lung cancer, indicating that tumor cells can process peptide precursors to bioactive amidated forms that may promote autocrine or paracrine growth signaling. This suggests that peptide amidation could contribute to cancer progression and represents a potential target for therapeutic intervention. The presence of amidated peptides in cancer cells also highlights the importance of understanding how the amidation machinery is co-opted in malignancy.
Peptide amidation and neurodegeneration
Amidation can influence the aggregation of amyloid-beta peptides, as shown for the Aβ(25-35) fragment, where amidation alters aggregation kinetics and fibril formation. This links peptide amidation to Alzheimer's disease and other neurodegenerative conditions where amyloid-beta aggregation is a key pathological feature. Understanding how amidation modifies amyloid-beta behavior may provide new insights into disease mechanisms and potential therapeutic strategies.
Peptide amidation in endocrine and neuroendocrine disorders
Because peptide amidation is required for the bioactivity of over half of all peptide hormones, defects in this process can lead to endocrine and neuroendocrine dysfunction. The processing of pro-ACTH/endorphin-derived peptides such as joining peptide exemplifies how amidation contributes to the production of mature hormones. Disruption of amidation could therefore affect stress responses, pain perception, and metabolic regulation, although specific human disorders linked to amidation defects require further investigation.
From peptide amidation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PAM abolish peptide amidation in vivo? | PAM knockout mouse or cell line |
| Which PAM domain is required for hydroxylation versus lyase activity? | Point mutations in PHM or PAL domains |
| Can a tagged PAM isoform rescue amidation defects? | Knock-in of tagged PAM |
| Does overexpression of PAM enhance amidation of specific substrates? | Overexpression of PAM in neuroendocrine cells |
| How does amidation affect amyloid-beta aggregation? | Amidated Aβ(25-35) peptide in aggregation assays |
| Is AMID involved in lung cancer peptide amidation? | AMID knockout or overexpression in lung cancer cells |
How to Study the peptide amidation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry | Mass shift due to amidation | Detection of amidated peptides in biological samples |
| Enzymatic activity assay | PHM and PAL catalytic activity | In vitro characterization of PAM function |
| CRISPR knockout screen | Loss of amidation due to gene disruption | Discovery of novel amidation regulators [2,3] |
| Thioflavin T fluorescence | Amyloid-beta aggregation kinetics | Assessing amidation effects on neurodegeneration |
| Electron microscopy | Fibril morphology | Structural analysis of amidated peptide aggregates |
| Western blot | Protein expression of PAM isoforms | Validating knockout or overexpression models |
| Immunofluorescence | Subcellular localization of PAM | Studying trafficking in secretory pathway |
| Peptide synthesis | Generation of amidated peptides | Production of standards for quantification [4,5] |
Mass spectrometry for detecting amidated peptides
Mass spectrometry is a key method for identifying and quantifying C-terminal alpha-amidated peptides, as the amidation introduces a mass shift that can be distinguished from the glycine-extended precursor. This approach allows researchers to confirm the occurrence of peptide amidation on specific substrates, such as joining peptide, and to assess the efficiency of the reaction in biological samples.
Enzymatic assays for PAM activity
In vitro enzymatic assays using synthetic glycine-extended peptide substrates can measure the two-step activity of PAM, including hydroxylation and lyase reactions. These assays typically monitor the formation of the amidated product using chromatographic or spectroscopic methods, and they are useful for dissecting the contributions of PHM and PAL domains.
CRISPR-based genetic screens
CRISPR knockout screens can identify genes required for peptide amidation by selecting for loss of amidated peptide production [2,3]. Such screens can be performed in neuroendocrine or cancer cell lines, using amidation-specific readouts such as mass spectrometry or antibody-based detection. This approach enables unbiased discovery of novel regulators of the pathway [2,3].
Biophysical studies of amidation effects on peptide aggregation
Amidation can alter the aggregation propensity of peptides such as amyloid-beta, and biophysical techniques including thioflavin T fluorescence and electron microscopy are used to study these effects. These methods provide insight into how amidation contributes to neurodegenerative disease mechanisms.
How CRISPR Can Be Used to Study GO:0001519 peptide amidation
Knockout
CRISPR knockout of PAM or other amidation-related genes can abolish peptide amidation, leading to accumulation of glycine-extended precursors and loss of bioactive amidated peptides. Such models are essential for establishing causality between amidation and physiological outcomes, and they can be used in cell lines or animal models to study hormone processing defects.
Point Mutation
Point mutations can be introduced into the catalytic domains of PAM to selectively disable hydroxylation or lyase activity, allowing dissection of the two-step mechanism. For example, mutating key residues in the PHM domain can block the first step, while PAL domain mutations block the second step, providing precise functional insights.
Knock-in
Knock-in of tagged or fluorescently labeled PAM allows real-time tracking of the enzyme and its substrates in living cells. This approach can also be used to introduce disease-associated mutations or to study isoform-specific functions by tagging endogenous PAM loci.
Overexpression
Overexpression of PAM or its substrates can enhance peptide amidation and increase the production of bioactive peptides, which is useful for studying gain-of-function effects in cancer or neuroendocrine cells [2,3]. Overexpression models can also help identify rate-limiting steps in the pathway.
How EDITGENE Supports peptide amidation Research
Researchers studying peptide amidation-related genes often need to determine whether a candidate gene is causally involved in the pathway, and CRISPR-based models provide the most direct way to test this. By combining knockout, point-mutation, knock-in, and overexpression strategies, it is possible to dissect the enzymatic steps, substrate specificity, and disease relevance of peptide amidation [2,3].
Contact EDITGENE today to design your custom CRISPR model for peptide amidation research.
Frequently Asked Questions About peptide amidation
What is peptide amidation (GO:0001519)?
Peptide amidation is the posttranslational conversion of C-terminal glycine-extended peptides to C-terminal alpha-amidated peptides, a modification required for the bioactivity of over half of all peptide hormones.
What genes are involved in peptide amidation?
The key gene is PAM, which encodes a bifunctional enzyme with both hydroxylating monooxygenase and alpha-amidating lyase activities; other genes include POMC, PCSK1, PCSK2, and Cpe, which are involved in precursor processing.
What enzymes catalyze peptide amidation?
The two steps are catalyzed by peptidyl-glycine alpha-hydroxylating monooxygenase (PHM) and peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL); in higher organisms, both activities reside on the bifunctional PAM polypeptide.
Why is peptide amidation important for hormone function?
Amidation is essential for the bioactivity of many peptide hormones, as it stabilizes the peptide and enables receptor binding; without it, hormones remain inactive or are rapidly degraded.
Is peptide amidation involved in cancer?
Yes, alpha-amidation of peptide hormones has been detected in lung cancer, suggesting that tumor cells can use this pathway for autocrine or paracrine signaling.
How does peptide amidation affect amyloid-beta aggregation?
Amidation of the Aβ(25-35) fragment alters its aggregation kinetics and fibril morphology, linking peptide amidation to neurodegenerative processes.
What methods are used to study peptide amidation?
Common methods include mass spectrometry to detect amidated peptides, enzymatic activity assays for PAM, CRISPR screens to identify regulators, and biophysical assays for aggregation studies [2,3,7].
Can CRISPR be used to study peptide amidation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of amidation genes and their functions in hormone processing and disease [2,3].
What is the role of PAM in peptide amidation?
PAM is the bifunctional enzyme that catalyzes both the hydroxylation of the C-terminal glycine and the subsequent cleavage to generate the alpha-amidated peptide.
What diseases are linked to peptide amidation defects?
Peptide amidation has been linked to cancer, particularly lung cancer, and to neurodegeneration through effects on amyloid-beta aggregation; endocrine disorders may also result from impaired hormone maturation [2,3,7].
Conclusion
Peptide amidation (GO:0001519) is a critical posttranslational modification that converts glycine-extended peptides into bioactive alpha-amidated hormones, a process required for over half of all peptide hormones. The two-step mechanism, catalyzed by PHM and PAL activities often combined in the bifunctional PAM enzyme, is central to endocrine and neuroendocrine signaling. Dysregulation of this pathway has been implicated in lung cancer and neurodegeneration, highlighting its clinical relevance [3,7]. CRISPR-based models offer powerful tools to dissect the genetic and mechanistic basis of peptide amidation, and EDITGENE provides comprehensive services to support such research [2,3].
References
- 2. Eipper BA et al.. 1986. Amidation of joining peptide, a major pro-ACTH/endorphin-derived product peptide.. J Biol Chem 261(19):8686-94 PMID: 3722167
- 3. Quinn KA et al.. 1991. Alpha-amidation of peptide hormones in lung cancer.. Cancer Cells 3(12):504-10 PMID: 1668141
- 4. Koyama A et al.. 2024. Twisted Amide-Mediated Peptide Synthesis.. Chemistry 30(65):e202403288 PMID: 39333757
- 5. Grigoropoulou M et al.. 2026. Peptide-directed solid-phase reductive amination.. Org Biomol Chem 24(12):2559-2569 PMID: 41800852
- 6. Henriksen DB et al.. 1993. Peptide amidation by enzymatic transacylation and photolysis.. Int J Pept Protein Res 41(2):169-80 PMID: 8458691
- 7. Etaka JCE et al.. 2025. Impact of Amidation on Aβ(25-35) Aggregation.. J Phys Chem B 129(8):2149-2158 PMID: 39945395
- 8. Crespo L et al.. 2005. Peptide and amide bond-containing dendrimers.. Chem Rev 105(5):1663-81 PMID: 15884786
